Candel Therapeutics (CADL) EBIT (2020 - 2023)
Historic EBIT for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to -$10.3 million.
- Candel Therapeutics' EBIT fell 2736.7% to -$10.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$38.4 million, marking a year-over-year decrease of 1057.0%. This contributed to the annual value of -$33.4 million for FY2024, which is 1307.6% up from last year.
- Latest data reveals that Candel Therapeutics reported EBIT of -$10.3 million as of Q4 2023, which was down 2736.7% from -$8.9 million recorded in Q3 2023.
- Candel Therapeutics' EBIT's 5-year high stood at -$2.6 million during Q2 2020, with a 5-year trough of -$10.3 million in Q4 2023.
- Over the past 4 years, Candel Therapeutics' median EBIT value was -$8.1 million (recorded in 2022), while the average stood at -$7.4 million.
- Per our database at Business Quant, Candel Therapeutics' EBIT plummeted by 19206.98% in 2021 and then increased by 22.52% in 2023.
- Candel Therapeutics' EBIT (Quarter) stood at -$6.1 million in 2020, then fell by 26.37% to -$7.7 million in 2021, then decreased by 4.66% to -$8.1 million in 2022, then fell by 27.37% to -$10.3 million in 2023.
- Its last three reported values are -$10.3 million in Q4 2023, -$8.9 million for Q3 2023, and -$9.6 million during Q2 2023.